The Ozarks Regional CCOP has been a collaborative endeavor between St. John's Regional Health Center and the Lester E. Cox Medical Centers since the first funding grant on August 15, 1987. Retention of key personnel (i.e. principal investigator and research nurse coordinator) have been very beneficial in maintaining continuity with administrative responsibility returning to St. John's Regional Health Center/ Mid-America Cancer Center (MACC). The MACC mission is to promote, on a regional basis, the reduction of morbidity and mortality resulting from cancer related diseases through education, prevention, detection, research, treatment and supportive services. The Ozarks Regional CCOP has demonstrated success in forming local alliances, integrating, networking and forming multidisciplinary teams. These teams support patients from initial screening and diagnosis staging to tertiary level therapies. Providing access to appropriate specialists and state of the art comprehensive cancer care is the direct result of the NCI grant awards. This continuation grant is necessary to further the progress of placing cancer patients from our community into NCI clinical research protocols. Grant continuation will allow expansion of clinical research using these committed multidisciplinary professional groups in the Ozarks region under NCI approved clinical treatment and cancer protocols. The purpose of which is to facilitate the development of the most effective treatment course for cancer therapy and cancer control. The Ozarks CCOP is instrumental in dissemination of the knowledge and technology made available through this national effort to physicians in Springfield and outlying communities. Research design and methods are provided by the NCI. Quality assurance activities reinforce the NCI standards. Since it's inception in August 1987 the Ozarks Regional CCOP has contributed to the national effort to collect valid data-regarding cancer therapies by placing 539 patients on NCI approved protocols. Continued funding is essential for this region to maintain community participation in cancer control research including prevention, early detection and patient management utilizing NCI standards. See Appendix A for documentation of tax exemption status for grant awardee.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (SRC (70))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
St. John's Regional Health Center
United States
Zip Code
Ahmed, Amina; Deng, Wei; Tew, William et al. (2018) Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol 150:300-305
Aghajanian, Carol; Filiaci, Virginia; Dizon, Don S et al. (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 150:274-281
Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8

Showing the most recent 10 out of 157 publications